Finance

Lists
LRMR:NASDAQ
Larimar Therapeutics Inc
$2.01
+1.26%
(+0.025) 1D
Oct 19, 10:50:30 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LRMR...
Open
$1.99
High
$2.02
Low
$1.96
Mkt. cap
208.80M
Avg. vol.
1.57M
Volume
183.37K
52-wk high
$6.42
52-wk low
$1.92
EPS
-$1.99
Beta
0.68
Shares outstanding
103.88M
No. of employees
71
Open
$1.99
High
$2.02
Low
$1.96
Mkt. cap
208.80M
Avg. vol.
1.57M
Volume
183.37K
52-wk high
$6.42
52-wk low
$1.92
EPS
-$1.99
Beta
0.68
Shares outstanding
103.88M
No. of employees
71
News stories
From web sources and news partners
About Larimar Therapeutics Inc
CEO-
Employees71
Founded2005
HeadquartersBala Cynwyd, Pennsylvania, United States
SectorBiotechnology
Websitelarimartx.com
Analyst ratings
Based on 4 analysts giving stock ratings to LRMR in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for LRMR in the last 3 months.
Highest
Current $2.01
$25.00 (+1,143.78%)
Average
$16.33 (+712.44%)
Lowest
$11.00 (+447.26%)
Analyst
Recommendation
Action
Price target
Projected
Date
Francois Brisebois
LifeSci Capital
Buy
Maintained
$25.00
+1,143.8%
09/28/2026
Jim Kelly
Leerink Partners
Buy
Maintained
$13.00
+546.8%
09/14/2026
Basma Radwan
Leerink Partners
Buy
Maintained
$13.00
+546.8%
09/14/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$13.00
+546.8%
09/14/2026
Laura Chico
Wedbush
Buy
Maintained
$11.00
+447.3%
08/05/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/05/2026
Ram Selvaraju
H.C. Wainwright
Buy
Initiated
$10.00
+397.5%
07/02/2026
Christopher Chen
Robert W. Baird
Buy
Maintained
$5.00
+148.8%
06/30/2026
Tessa Romero
J.P. Morgan
Buy
Reiterated
$9.00
+347.8%
06/29/2026
Samantha Semenkow
Citi
Buy
Maintained
$14.00
+596.5%
06/30/2026
Catherine Novack
JonesTrading
Buy
Maintained
$13.00
+546.8%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
44.83M
59.17M
24.93M
27.80M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.67M
4.84M
6.19M
6.55M
Operating expense
49.50M
64.02M
31.12M
34.35M
Total operating expenses
49.50M
64.02M
31.12M
34.35M
Operating income
-49.50M
-64.02M
-31.12M
-34.35M
Other non operating income
1.79M
1.52M
1.50M
1.57M
EBT including unusual items
-47.71M
-62.50M
-29.61M
-32.78M
EBT excluding unusual items
-47.71M
-62.50M
-29.61M
-32.78M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-47.71M
-62.50M
-29.61M
-32.78M
Net profit margin
-
-
-
-
Earnings per share
-0.61
-0.73
-0.31
-0.30
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-49.41M
-63.93M
-31.05M
-34.29M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps